All In Biotech

Drug Trial Radar · NCT07015697

A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

A Phase 1, Multicenter Trial of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

17

Actual

Start

Jul 17, 2025

Primary completion

Dec 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
Collaborators
AstraZeneca
First posted
Jun 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This dose escalation and dose expansion study was designed to assess the safety, tolerability, PK and efficacy of subcutaneous T-DXd in participants with metastatic solid tumors.

Conditions

  • Recurrent or Metastatic Solid Tumors

Interventions

  • Trastuzumab DeruxtecanDrug

    Dose Escalation Part: Trastuzumab Deruxtecan will be administered at escalating doses to determine the RDE. Expansion Part: Trastuzumab Deruxtecan will be administered at RDE.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing a Treatment Emergent Adverse Event (TEAE)Time frame: From the start of trial intervention to 21 days after the last dose, up to approximately 9 months
  2. Area Under Curve (AUC)Time frame: From the start of trial intervention to last dose, up to approximately 9 months
  3. Number of Participants with Dose limiting toxicities (DLT) During the Dose-Escalation PhaseTime frame: From the start of trial intervention to 21 days after the last dose, up to approximately 9 months

Locations

31 sites in 7 countries. Site status is shown where the registry gives one.

  • Research Site

    Newport Beach, California

  • Research Site

    Atlanta, Georgia

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Maumee, Ohio

  • Research Site

    Nashville, Tennessee

  • Research Site

    Asa Sul, Brazil

  • Research Site

    Goiás, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Santo André, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site Saint

    Herblain, France

  • Research Site

    Rennes, France

  • Research Site

    Chiba, Japan

  • Research Site

    Kanagawa, Japan

  • Research Site

    Tokyo, Japan

  • Research Site

    Tokyo, Japan

  • Research Site

    Tokyo, Japan

  • Research Site

    Seongnam-si, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Barcelona, Spain

  • Research Site

    Madrid, Spain

  • Research Site

    Seville, Spain

  • Research Site

    Taichung, Taiwan

  • Research Site

    Tainan, Taiwan

  • Research Site

    Taipei, Taiwan

  • Research Site

    Taipei, Taiwan

  • Research Site

    Taoyuan City, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.